Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort.
Schizophrenia Research. 2018-05-01; 195: 357-365
DOI: 10.1016/j.schres.2017.09.027
Lire sur PubMed
1. Schizophr Res. 2018 May;195:357-365. doi: 10.1016/j.schres.2017.09.027. Epub
2017 Sep 30.
Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from
the first-step national FACE-SZ cohort.
Fond G(1), Boyer L(2), Leboyer M(3), Godin O(4), Llorca PM(5), Andrianarisoa
M(3), Berna F(6), Brunel L(3), Aouizerate B(7), Capdevielle D(8), Chereau I(5),
D’Amato T(9), Dubertret C(10), Dubreucq J(11), Faget C(12), Gabayet F(11),
Mallet J(10), Misdrahi D(13), Rey R(9), Lancon C(12), Passerieux C(14), Roux
P(14), Vidailhet P(6), Yazbek H(8), Schürhoff F(3), Bulzacka E(3); FACE-SZ
(FondaMental Academic Centers of Expertise for Schizophrenia) group.
Collaborators: Andrianarisoa M(15), Aouizerate B(16), Berna F(17), Blanc O(18),
Brunel L(15), Bulzacka E(15), Capdevielle D(19), Chereau-Boudet I(18),
Chesnoy-Servanin G(20), Danion J(17), D’Amato T(20), Deloge A(21), Delorme
C(22), Denizot H(18), Dorey JM(20), Dubertret C(23), Dubreucq J(22), Faget
C(24), Fluttaz C(22), Fond G(15), Fonteneau S(25), Gabayet F(22), Giraud-Baro
E(22), Hardy-Bayle MC(25), Lacelle D(18), Lançon C(24), Laouamri H(26), Leboyer
M(15), Le Gloahec T(15), Le Strat Y(23), Llorca(18), Mallet J(27), Metairie
E(24), Misdrahi D(21), Offerlin-Meyer I(17), Passerieux C(25), Peri P(24), Pires
S(18), Portalier C(23), Rey R(20), Roman C(22), Sebilleau M(25), Schandrin
A(19), Schurhoff F(15), Tessier A(21), Tronche A(15), Urbach M(25), Vaillant
F(24), Vehier A(20), Vidailhet P(17), Vilà E(21), Yazbek H(19), Zinetti-Bertschy
A(17).
Author information:
(1)Fondation FondaMental, Créteil, France. Electronic address:
.
(2)Fondation FondaMental, Créteil, France; Pôle Psychiatrie Universitaire, CHU
Sainte-Marguerite, F-13274 Marseille cedex 09, France.
(3)Fondation FondaMental, Créteil, France; INSERM U955, Créteil, France; Paris
Est University, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux Universitaires H
Mondor, Créteil, France; Translational Psychiatry Team, Créteil, France.
(4)Fondation FondaMental, Créteil, France; Sorbonne Universités, UPMC Univ Paris
06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique,
F-75013 Paris, France; INSERM, UMR_S 1136, Institut Pierre Louis d’Epidémiologie
et de Santé Publique, F-75013 Paris, France.
(5)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France.
(6)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(7)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, F-33076 Bordeaux, France; Inserm, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, U862, F-33000 Bordeaux, France.
(8)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm, 1061, Montpellier, France.
(9)Fondation FondaMental, Créteil, France; Université Claude Bernard Lyon 1,
Centre Hospitalier Le Vinatier, Pole Est BP 300 39 – 95 bd Pinel, 69678 Bron
Cedex, France.
(10)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot,
Sorbonne Paris Cité, Faculté de Médecine, France.
(11)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(12)Fondation FondaMental, Créteil, France; Assistance Publique des Hôpitaux de
Marseille (AP-HM), Pôle Universitaire de Psychiatrie, Marseille, France.
(13)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, F-33076 Bordeaux, France; CNRS UMR 5287-INCIA, France.
(14)Fondation FondaMental, Créteil, France; Service de psychiatrie d’adulte,
Centre Hospitalier de Versailles, UFR des Sciences de la Santé Simone Veil,
Université Versailles Saint-Quentin en Yvelines, Versailles, France.
(15)AP-HP, DHU Pe-PSY, Pôle de Psychiatrie et d’addictologie des Hôpitaux
Universitaires H Mondor, INSERM U955, Eq 15 Psychiatrie Translationelle,
Université Paris Est-Créteil, Créteil, France; Fondation Fondamental, France.
(16)Centre Hospitalier Charles Perrens, F-33076 Bordeaux, France; Université de
Bordeaux, Inserm, Neurocentre Magendie, Physiopathologie de la Plasticité
Neuronale, U862, F-33000 Bordeaux, France; Fondation Fondamental, France.
(17)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France; Fondation Fondamental, France.
(18)CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69 63003
Clermont-Ferrand Cedex 1, France; Fondation Fondamental, France.
(19)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm, 1061 Montpellier, France;
Fondation Fondamental, France.
(20)Université Claude Bernard Lyon 1, Centre Hospitalier Le Vinatier, Pole Est
BP 300 39 – 95 bd Pinel, 69678 Bron Cedex, France; Fondation Fondamental,
France.
(21)Centre Hospitalier Charles Perrens, F-33076 Bordeaux, France; Université de
Bordeaux, CNRS UMR 5287-INCIA, France; Fondation Fondamental, France.
(22)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France; Fondation Fondamental, France.
(23)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
U894 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, France;
Fondation Fondamental, France.
(24)Assistance Publique des Hôpitaux de Marseille (AP-HM), Pôle Universitaire de
Psychiatrie, Marseille, France; Fondation Fondamental, France.
(25)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, Le
Chesnay, EA 4047 HANDIReSP, UFR des Sciences de la Santé Simone Veil, Université
Versailles Saint-Quentin en Yvelines, Versailles, France; Fondation Fondamental,
France.
(26)Fondation Fondamental, France.
(27)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
U894 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, France;
Assistance Publique des Hôpitaux de Marseille (AP-HM), Pôle Universitaire de
Psychiatrie, Marseille, France.
OBJECTIVES: Sex differences can yield important clues regarding illness
pathophysiology and its treatment. Schizophrenia (SZ) has a lower incidence
rate, and a better prognosis, in women versus men. The present study
investigated the cognitive profiles of both sexes in a large multi-centre sample
of community-dwelling SZ patients.
METHOD: 544 community-dwelling stable SZ subjects (141 women and 403 men; mean
age 34.5±12.1 and 31.6±8.7years, respectively) were tested with a comprehensive
battery of neuropsychological tests.
RESULTS: Although community-dwelling SZ men had more risk factors for impaired
cognition (including first-generation antipsychotics administration and comorbid
addictive disorders), women had lower scores on a wide range of cognitive
functions, including current and premorbid intellectual functioning, working
memory, semantic memory, non-verbal abstract thinking and aspects of visual
exploration. However, women scored higher in tests of processing speed and
verbal learning, as well as having a lower verbal learning bias. No sex
difference were evident for visuospatial learning abilities, cued verbal recall,
sustained attention and tests of executive functions, including cognitive
flexibility, verbal abstract thinking, verbal fluency and planning abilities.
CONCLUSION: Sex differences are evident in the cognitive profiles of SZ
patients. The impact on daily functioning and prognosis, as well as longitudinal
trajectory, should be further investigated in the FACE-SZ follow-up study. Sex
differences in cognition have implications for precision-medicine determined
therapeutic strategies.
LIMITS: Given the restricted age range of the sample, future research will have
to determine cognitive profiles across gender in late onset SZ.
Copyright © 2017 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.schres.2017.09.027
PMID: 28974404 [Indexed for MEDLINE]